Changes in fractional tumor viability and proliferative fraction were assessed by comparing differences in caspase-3 and Ki-67, respectively, between the baseline biopsy and the surgical resection performed following the second cycle of chemotherapy. This evidence concerns the gene CASP3 and neoplasm.